Latest Market Entry Strategy News

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

Bio-Gene Technology Limited has received a $519,500 R&D tax incentive from the Australian government, supporting its development of innovative bio-insecticides targeting insecticide resistance.

Airtasker Limited has announced a $10 million equity capital raise to accelerate marketing efforts in the UK and US, following a strong first quarter with group revenue up 20.5% year-on-year. Strategic partnerships, including a cornerstone investment from iHeartMedia, underpin its international growth ambitions.

AnteoTech has formalized a joint development and sales agreement with US-based Black Diamond Structures to co-develop an advanced battery product targeting high silicon lithium-ion anodes in the US market.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

1414 Degrees Ltd advances its transformation into a full-service decarbonised energy provider, delivering key technology and commercial milestones in Q3 FY25 while maintaining a stable cash position.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

Smart Parking Limited has reported robust H1 FY25 results, underpinned by a strategic acquisition of Peak Parking LP and a fully underwritten $45 million equity raise to fund its US expansion.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

Ovanti Limited has made significant strides in its plan to enter the US Buy Now Pay Later market, delivering a comprehensive strategic report and strengthening its executive team to support expansion.

EZZ Life Science Holdings delivered a robust Q2 FY25 with a 16.6% increase in customer receipts and a 308% jump in operating cash flows, while gearing up for US market entry and expanding its global footprint.